Over time, extensive R&D on the potential healthbenefits of cannabis, have enabled medical researchers to identify a number ofpharmacologically active ingredients that offer clinical benefit, minus theaddictive properties of the crude substance. Currently, several stakeholders inthe pharmaceutical industry are actively engaged in the efforts to developleads based on natural and synthetic derivatives of cannabinoids.
To order this 250+ page report, which features 140+ figuresand 170+ tables, please visit this -https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html
The over USD 5 billion (by 2030)financial opportunity within the endocannabinoid system targeted therapeutics market has been analyzed across thefollowing segments:
§ Target Disease Indication
§ Cancer
§ Genetic Disorders
§ Neurological Indications
§ Others
§ Route of Administration
§ Oral
§ Inhalation
§ Key Geographies
§ North America
§ Europe
Asia-Pacific and theRest of the World
The “Endocannabinoid System Targeted Therapeutics Market, 2020-2030" reportfeatures the following companies, which we identified to be key players in thisdomain:
§ GW Pharmaceuticals
§ Corbus Pharmaceuticals
§ Tilray
§ Tetra Bio-Pharma
§ Botanix Pharmaceuticals
§ Kalytera Therapeutics
§ Therapix Biosciences
§ Echo Pharmaceuticals
§ Avicanna
§ GB Sciences
Table of Contents
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. MARKET LANDSCAPE: ENDOCANNABINOIDSYSTEM TARGETED THERAPEUTICS
5. COMPANY PROFILES
6. ACADEMIC GRANTS ANALYSIS
7. PARTNERSHIPS AND COLLABORATIONS
8. MERGERS AND ACQUISITIONS
9. DRUG DEVELOPMENT STRATEGY ANALYSIS
10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
11. CONCLUDING REMARKS
12. EXECUTIVE INSIGHTS
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
To purchase a copy,please visit https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html
Contact Details
GauravChaudhary
+1(415) 800 3415
